- Phase 1b study of BIIB080/IONIS-MAPT Rx met primary objective of safety and tolerability
- Study demonstrated durable, robust, time and dose dependent lowering of tau protein in cerebrospinal fluid
PR Newswire
CAMBRIDGE, Mass. and CARLSBAD, Calif., July 26, 2021